高血压合并新型冠状病毒感染,ACEI/ARB用还是不用?  

Hypertension complicated with novel coronavirus infection,ACEI/ARB use or not?

作　　者：周子华[1] ZHOU Zihua(Department of Cardiology,Union Hospital,Huazhong University of Science and Technology,Wuhan,430022,China)

机构地区：[1]华中科技大学同济医学院附属协和医院心内科,武汉430022

出　　处：《临床心血管病杂志》2020年第8期687-688,共2页Journal of Clinical Cardiology

基　　金：华中科技大学自主创新基金(新冠肺炎专项)。

摘　　要：新型冠状病毒在国内传播流行的威胁仍然存在。新型冠状病毒肺炎(COVID-19)患者中,合并高血压的比例较高。新型冠状病毒通过与肺泡等细胞膜上的血管紧张素转换酶2(ACE2)结合进入机体,并引起后续病变,有证据显示血管紧张素转换酶抑制剂/血管紧张素受体拮抗剂(ACEI/ARB)类降压药物可以升高ACE2的表达,因此COVID-19合并高血压的患者是否应用ACEI/ARB存在一定争论。本文对应用ACEI/ARB的利弊作简要介绍。The threat of the novel coronavirus spreading in China still exists.The proportion of hypertensive patients with novel coronavirus pneumonia(COVID-19)is relatively high.Due to the combination of the novel coronavirus with ACE2 on the alveolar membrane and causing subsequent lesions,and ACEI/ARB antihypertensive drugs can increase the expression of ACE2,so there is a certain controversy about whether to use ACEI/ARB in hypertensive patients complicated with COVID-19.In this paper,the advantages and disadvantages of ACEI/ARB will be briefly introduced.

关 键 词：新型冠状病毒肺炎 高血压 转换酶抑制剂 AT1受体拮抗剂 

分 类 号：R544.1[医药卫生—心血管疾病]